Should anticoagulation (e.g., apixaban) be stopped after a fall resulting in intracranial hemorrhage?

Should Anticoagulation Be Stopped After a Fall Resulting in Intracranial Hemorrhage?

Yes, apixaban must be discontinued immediately upon diagnosis of intracranial hemorrhage (ICH), and rapid reversal should be performed as soon as possible, regardless of whether coagulation test results are available. 1, 2, 3

Immediate Management: Stop and Reverse

When ICH occurs in a patient on apixaban:

• Discontinue apixaban immediately upon ICH diagnosis 3
• Administer andexanet alfa for rapid reversal of Factor Xa inhibitors like apixaban 2
  • Low-dose regimen: 400 mg IV bolus followed by 4 mg/min infusion for 120 minutes if last apixaban dose ≤5 mg was taken <8 hours prior
  • High-dose regimen: 800 mg IV bolus followed by 8 mg/min infusion for 120 minutes if last apixaban dose >5 mg was taken <8 hours prior
• If andexanet alfa is unavailable, use prothrombin complex concentrate (PCC) or activated PCC 2, 3
• Consider activated charcoal if apixaban was ingested within 2-4 hours 2

The 2022 AHA/ASA guideline emphasizes that reversal should be initiated based on timing and type of anticoagulant rather than waiting for laboratory confirmation, as delays worsen outcomes 1.

Critical Pitfall: Active Bleeding is an Absolute Contraindication

The FDA label explicitly states that active pathological bleeding is a contraindication to apixaban 3. This means you cannot continue apixaban during acute ICH—doing so would violate the drug's contraindications and expose the patient to potentially fatal hemorrhage expansion.

The Question of Restarting: A Nuanced Decision

After the acute phase, the decision becomes more complex. The FDA warns that premature discontinuation without adequate alternative anticoagulation increases thrombotic risk, including stroke 3. However, this must be balanced against ICH recurrence risk.

When to Consider Restarting:

Timing considerations based on available evidence:

• Most retrospective studies suggest anticoagulation can be safely restarted in select patients within 1-4 weeks after ICH 4, 5
• Older data from high-risk patients (mechanical valves) showed 1-2 weeks off anticoagulation carried low embolic risk (2.6-4.8% at 30 days) 6, 7

Patient stratification for restart decisions:

Higher priority for restarting (greater thrombotic risk):

• Mechanical heart valve prosthesis (especially mitral position, cage-ball valves) 5, 7
• Atrial fibrillation with prior cardioembolic stroke 6
• Recent venous thromboembolism at high recurrence risk 5

Lower priority for restarting (greater hemorrhagic risk):

• Lobar ICH location (suggests cerebral amyloid angiopathy) 5
• Uncontrolled hypertension or other non-amendable ICH risk factors 5
• Poor baseline functional status or limited life expectancy 4

Safer restart profile with apixaban:

• For non-valvular atrial fibrillation, direct oral anticoagulants like apixaban appear reasonable after deep ICH 5
• Recent meta-analysis suggests apixaban may have comparable or lower intracranial hemorrhage risk versus aspirin (relative risk 0.67, though not statistically significant) 8

Restart Protocol When Appropriate:

1. Ensure hemorrhage stability on repeat neuroimaging before considering restart 4, 9
2. Do not use loading doses when restarting apixaban after ICH 9
3. Optimize blood pressure control and address modifiable ICH risk factors 1
4. Consider multidisciplinary input from neurology/neurosurgery, cardiology, and hematology 9

Key Algorithmic Approach:

1. Acute ICH diagnosed → Stop apixaban immediately + reverse with andexanet alfa
2. Days 1-14: Keep off anticoagulation, monitor hemorrhage evolution with serial imaging
3. Week 2-4: Assess thrombotic risk stratification:
   • High thrombotic risk (mechanical valve, recent stroke) + deep ICH + stable imaging → Consider restart at 7-14 days
   • Moderate thrombotic risk (atrial fibrillation without prior stroke) + deep ICH → Consider restart at 2-4 weeks
   • Lobar ICH or uncontrolled risk factors → Delay longer or avoid restart; consider left atrial appendage closure for atrial fibrillation patients
4. When restarting: Use standard maintenance dose without loading, ensure close monitoring

Critical Warning About Renal Function:

A recent case report highlights that apixaban can cause catastrophic multi-site hemorrhages (pleural, pericardial, intracranial) in patients with end-stage kidney disease, even at guideline-recommended doses 10. In patients with severe CKD/ESKD, extreme caution is warranted, and apixaban may need permanent discontinuation despite thrombotic risk.

The evidence base for optimal timing remains limited by lack of randomized trials 4, 5, 11, but the consistent finding across retrospective studies is that temporary discontinuation for 1-2 weeks carries acceptable embolic risk in most patients, while early recurrence of ICH after restart is uncommon 6, 7.